GE HealthCare Technologies, spun off from General Electric in 2023, has shown significant stock growth, outperforming the S&P 500 by a wide margin. Despite mixed financial performance, the company remains undervalued compared to competitors, with potential for further growth in a large, expanding market. Management's optimistic guidance for 2024 and beyond, coupled with strategic investments and partnerships, supports continued revenue and profit growth.
GE HealthCare announces the launch of a Care Innovation Hub, a joint research collaboration with the University of California, San Francisco.
GEHC's continued focus on innovations, acquisitions and partnerships raises optimism about the stock.
GE HealthCare announces a seven-year strategic collaboration with Sutter Health.
Investors interested in Medical - Products stocks are likely familiar with GE HealthCare Technologies (GEHC) and Insulet (PODD). But which of these two stocks is more attractive to value investors?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
GE HealthCare Technologies Inc. GEHC shares are trading higher Wednesday. The stock was upgraded from Hold to Buy, while the price target was raised from $95 to $103 by Jefferies.
Investors interested in stocks from the Medical - Products sector have probably already heard of GE HealthCare Technologies (GEHC) and Insulet (PODD). But which of these two companies is the best option for those looking for undervalued stocks?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
GE HealthCare shares have surged nearly 27% since October 2023, driven by AI-driven strategies and innovation in healthcare diagnostics, despite some volatility in revenue growth. The bullish outlook for 2025 is supported by GEHC's AI advancements, expected sales and profitability improvements, and a significant backlog of $19.6 billion. AI-driven healthcare solutions are projected to enhance diagnostic accuracy, reduce treatment costs, and drive market growth, with GEHC positioned as a leader with numerous FDA-approved devices.
GEHC's continued focus on innovations, acquisitions and partnerships raises optimism about the stock.
GE HealthCare Technologies is rated a buy due to strong growth prospects, a healthy backlog, and favorable valuation compared to peers. The company's revenue growth is supported by new product innovations, including the FDA-approved Flyrcado, and potential recovery in Chinese demand. Margins are expected to improve through cost optimization, volume leverage, and strategic pricing, with a medium-term EBIT margin target of high teens to 20%.